MetaCap

Atea Pharmaceuticals (AVIR) vs Evommune (EVMN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Atea Pharmaceuticals (AVIR) has outperformed Evommune (EVMN) over the past year, gaining 33.3% versus a loss of 62.4%. Atea Pharmaceuticals is the larger company by market cap ($318.0 million vs $291.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVIR+33.33%EVMN-62.37%
+116%+17%-82%
Nov 21, 20251 yearNov 20, 2026
AVIR+21.10%EVMN-61.76%
+94%+7%-80%
Nov 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVIR versus EVMN key metrics
MetricAVIREVMN
Share price$3.96$7.04
Market cap$318.00M$291.10M
1-day change+0.76%-2.76%
YTD return+10.92%-58.88%
1-year return+33.33%-62.37%
5-year return-51.35%—
EPS (TTM)$-1.95$-3.83
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$13.00M
Revenue growth (YoY)—+85.71%
Net income (latest FY)$-158.35M$-68.87M
Operating margin—-623.62%
Net margin—-529.77%
52-week high$6.45$33.20
52-week low$2.96$4.94
Distance from 52-week high-38.60%-78.80%
Analyst consensusbuybuy
Avg. price target upside+127.27%+210.94%
Average volume290.60K841.65K
Shares outstanding80.30M41.35M
Employees5548
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AVIR has outperformed EVMN by 95.7 percentage points over the past year.

About Atea Pharmaceuticals

AVIR stock →

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

About Evommune

EVMN stock →

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees

AVIR vs EVMN FAQ

Which is bigger, Atea Pharmaceuticals or Evommune?

Atea Pharmaceuticals (AVIR) is larger, with a market capitalization of $318.00M compared with $291.10M for Evommune (EVMN).

Which stock has performed better over the past year, AVIR or EVMN?

AVIR returned +33.33% over the past 12 months, compared with -62.37% for EVMN (price return, excluding dividends). Past performance does not predict future results.

Are Atea Pharmaceuticals and Evommune in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons